Patents by Inventor Mehran Nikan

Mehran Nikan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240084297
    Abstract: Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.
    Type: Application
    Filed: February 16, 2023
    Publication date: March 14, 2024
    Inventors: Anastasia KHVOROVA, Mehran NIKAN, Matthew HASSLER, Maire OSBORN, Reka HARASZTI, Andrew COLES, Anton TURANOV, Neil ARONIN, Annabelle BISCANS
  • Publication number: 20230338555
    Abstract: Disclosed herein are compounds that comprise an oligonucleotide, a conjugate linker, and a conjugate moiety capable of interacting with a cell surface moiety, wherein the oligonucleotide and the conjugate moiety are connected via the conjugate linker. The conjugate moiety may comprise a cell-targeting moiety and a peptide extender. In general, peptide extenders have sufficient length and/or structure to reduce or prevent interaction between the oligonucleotide and the cell-targeting moiety. Such compounds are useful to treat, prevent or ameliorate a condition or disease in an individual with limited off-target effects.
    Type: Application
    Filed: May 18, 2021
    Publication date: October 26, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Mehran Nikan, Michael Tanowitz, Chrissa A. Dwyer, Frank Rigo, Punit P. Seth
  • Patent number: 11753638
    Abstract: Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 12, 2023
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Mehran Nikan, Matthew Hassler, Maire Osborn, Reka Haraszti, Andrew Coles, Anton Turanov, Neil Aronin, Annabelle Biscans
  • Publication number: 20200339983
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Application
    Filed: March 9, 2020
    Publication date: October 29, 2020
    Inventors: Anastasia Khvorova, Mehran Nikan, Matthew Hassler, Maire Osborn, Reka Haraszti, Andrew Coles, Anton Turanov, Neil Aronin
  • Publication number: 20200268898
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Application
    Filed: November 7, 2018
    Publication date: August 27, 2020
    Inventors: Brett P. MONIA, Thazha P. PRAKASH, Garth A. KINBERGER, Richard LEE, Punit P. SETH, Michael OESTERGAARD, Mehran NIKAN, Shalini ANDERSSON, Eva Carina AMMALA, Daniel Laurent KNERR, Maria OLWEGARD-HALVARSSON, William John DRURY, III, Eric VALEUR
  • Patent number: 10633653
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: April 28, 2020
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Mehran Nikan, Matthew Hassler, Maire Osborn, Reka Haraszti, Andrew Coles, Anton Turanov, Neil Aronin
  • Publication number: 20190185855
    Abstract: Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 20, 2019
    Inventors: Anastasia KHVOROVA, Mehran NIKAN, Matthew HASSLER, Maire OSBORN, Reka HARASZTI, Andrew COLES, Anton TURANOV, Neil ARONIN, Annabelle BISCANS
  • Publication number: 20170043024
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Application
    Filed: August 12, 2016
    Publication date: February 16, 2017
    Inventors: Anastasia Khvorova, Mehran Nikan, Matthew Hassler, Maire Osborn, Reka Haraszti, Andrew Coles, Anton Turanov, Neil Aronin